Parkinson's Disease PhD: Mapping Mitochondrial DNA Modifications and Their Disease Links

Parkinson's Disease PhD: Mapping Mitochondrial DNA Modifications and Their Disease Links

Assessment: Promising with material uncertainties. This Exeter project stands out because it will test whether long-read sequencing can reliably identify mitochondrial DNA (mtDNA) modifications before applying the method to Parkinson’s disease (PD) brain samples. The intended PhD combines assay validation, mitochondrial genetics, human brain data and multi-omics. It may suit candidates who can show relevant biomedical or computational research experience and want to work across experimental and analytical tasks.

The project is part of Exeter’s MRC Functional Genomics Doctoral Landscape Award (FGx-DLA). The current award page describes a four-year studentship, UK tuition-fee funding and a £21,805 stipend for 2026/27, subject to annual updates. The deadline is unresolved: the project specification gives 8 December 2026, while the current Exeter award page gives 5 January 2027. Plan around 8 December until Exeter confirms otherwise. The current FGx-DLA programme page says international students at Exeter do not need to supplement UKRI funding for the international-fee difference. This resolves the programme-level top-up question for Exeter project 6025; check that the written offer reflects the policy and specifies annual fee rates and any other charges. Official project specification, current award page, FGx-DLA international fee guidance

Research Problem and Doctoral Work

Mitochondrial DNA may carry chemical modifications that affect gene regulation, but the kinds of modifications present, their abundance and their functional importance remain unsettled. Conventional methylation assays can create artefacts when applied to mtDNA. The project therefore treats measurement reliability as a central scientific question. It proposes that reproducible mtDNA modification patterns may influence mitochondrial genome regulation and change in PD. Official project specification

The advertised doctoral work has three connected parts:

1. Build and validate the assay. Enrich native mtDNA and use Oxford Nanopore Technologies (ONT) long-read sequencing to measure sequence variation and candidate modifications on individual molecules. Generate artificial mtDNA molecules with known modification levels to test sensitivity, specificity and reproducibility. Marks named as examples include 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC) and 6-methyladenine (6mA).

2. Map modifications in PD brain. Apply the validated approach to an existing, well-characterised PD case-control brain cohort. The project aims to measure the distribution and abundance of modifications across the mitochondrial genome, examine sequence variants and heteroplasmy, and test the hypothesis that regulatory regions such as the D-loop matter in PD.

3. Test molecular associations. Examine whether modification variation, especially in regulatory regions, is associated with mitochondrial transcription and mtDNA abundance. Then integrate the profiles with existing bulk RNA-seq, single-nucleus RNA-seq, small-RNA sequencing, nuclear DNA methylation and genetic data to relate mtDNA states to cellular pathways and PD-associated molecular changes.

These analyses may prioritize candidate regulatory modifications, but an association would not show that a modification causes PD or changes gene expression. The project describes mitochondrial epigenome editing as a possible future causal-investigation route; it is not a promised experiment within this PhD. The cohort and matched data are described as existing, which may reduce the need for expensive new data generation. The project sheet does not state sample size, brain regions, sample-access conditions or the exact data inventory. Official project specification

School, Programme and Field Context

The project specification names the University of Exeter as the primary institution and the Department of Clinical & Biomedical Sciences as the department. The award is part of a national four-year MRC training programme involving Exeter, Cambridge, Edinburgh, Imperial, King’s and Oxford, with shared and often cross-institutional training. Patrick Chinnery’s Cambridge affiliation adds mitochondrial-genetics expertise, but the available material does not describe a Cambridge registration or joint degree. Official project specification, FGx-DLA programme page

Exeter’s published institutional rankings are #136 in the QS World University Rankings 2027 and joint #170 in the Times Higher Education World University Rankings 2026. These are overall university rankings. Its REF 2021 results provide a more subject-oriented but historical signal: the university reported 18th nationally for research power overall, and its Biological Sciences submission comprised 41% 4-star, 49% 3-star and 10% 2-star activity. Clinical and Biomedical Sciences describes research themes in neuroscience, genomics, epigenetics and data science that align with parts of this project. These signals indicate broad research capacity; none ranks this individual PhD or guarantees access to particular facilities. Exeter rankings, REF 2021 results, Clinical and Biomedical Sciences research

The award page says students take part in shared training, scientific meetings and cross-institutional activities. The project sheet describes existing samples, matched datasets, sequencing and computational infrastructure, but does not identify a specific lab location, instrument allocation, formal registration route or required training schedule. Exeter’s general ONT facility guidance notes the importance of high-quality, high-molecular-weight DNA and warns that contamination or DNA damage can affect quality. This is relevant technical context, not confirmation that the project will use that facility. FGx-DLA programme page, Exeter ONT DNA sample guidance

Supervisor and Lab Assessment

The lead supervisor is Professor Katie Lunnon, based at Exeter. Her university profile describes dementia genomics and epigenetics. The project sheet credits her with neurodegeneration epigenetics and prior work on the human-brain mitochondrial epigenome. It describes Professor Patrick Chinnery as bringing mitochondrial-genetics, long-read and multi-omics expertise; Dr Morteza Kouhsar as contributing long-read bioinformatics and multi-omics integration; and Dr Adam Smith as experienced in developing ONT approaches. Kouhsar’s NIHR Exeter profile independently describes bioinformatics, omics, epigenetics, RNA-seq, small-RNA analysis, R/Python and machine-learning experience. Chinnery’s MRC Cambridge group works on mitochondrial genomics and inherited or acquired mitochondrial and nuclear DNA variation. This is a complementary team profile, though meeting frequency and each person’s day-to-day supervisory role are not specified. Katie Lunnon profile, Morteza Kouhsar profile, Chinnery Group, official project specification

Recent Important Publications

Several papers make the assay question particularly important:

• Devall et al. (2022), “Genome-wide characterization of mitochondrial DNA methylation in human brain.” Using targeted bisulfite sequencing in superior temporal gyrus and cerebellum from seven donors, the Exeter-led study reported relatively low but conserved methylation patterns, including D-loop peaks and mainly non-CpG signal. The small donor count and bisulfite method limit what can be concluded about mark identity and artefacts. It gives a direct brain-tissue precedent for the proposed research. PubMed record
• Bicci et al. (2021), “Single-molecule mitochondrial DNA sequencing shows no evidence of CpG methylation in human cells and tissues.” The ONT study, with Patrick Chinnery as a co-author, identified sequence-specific false-positive calls and concluded that CpG signal did not exceed its negative-control error threshold in the samples tested. This is a direct reason to demand calibrated controls and threshold criteria. Its conclusion concerns the tested CpG signal, not every modification or context named in the new project. PubMed record
• Stoccoro et al. (2021), “Mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Parkinson’s disease patients.” In 30 PD patients and 30 matched controls, the team found no D-loop methylation or copy-number difference in peripheral blood. The modest sample size and blood tissue limit generalization to a whole-brain analysis, but the null finding is important context for the proposed D-loop hypothesis. PubMed record
• Smith et al. (2023), “New mitochondrial DNA methylation profiling method confirms epigenetic marker in the brain.” This conference-supplement abstract describes enriched mtDNA, 0%, 50% and 100% long-range PCR controls, and ONT-based profiling, reporting low but conserved methylation peaks. It is closely related method work, but the available item is an abstract rather than a full research article. Publisher abstract
• Harvey et al. (2026), “Interrogating DNA methylation associated with Lewy body pathology in a cross-brain-region and multi-cohort study.” Exeter collaborators report a large cortical methylation meta-analysis related to Lewy body pathology. It shows recent team experience in brain-bank cohorts and epigenomic integration, but it investigates nuclear DNA methylation, not mtDNA modifications. Nature Communications article

Independent field findings extend the debate. A 2026 early-onset PD blood study reported 5mC/5hmC differences using bisulfite and oxidative-bisulfite sequencing; a 2025 human-brain study separately analysed 5mC and 5hmC in enriched neuronal populations but did not directly test mtDNA. A 2025 PD cerebellum study found higher mtDNA copy number in a multi-bank brain dataset, while a 2024 blood study found apparent mtDNA copy-number associations weakened after adjustment for blood-cell composition. Together these results emphasize the need to distinguish tissue, assay, cell composition, sequence variation and abundance effects. They do not settle whether a particular mtDNA mark causes PD. 2026 early-onset PD study, 2025 human-brain methylation study, 2025 cerebellum mtDNA copy-number study, 2024 blood mtDNA copy-number study

Parkinson’s disease is a substantial research problem: the WHO reports more than 8.5 million people living with PD globally in 2019, with prevalence having doubled over the preceding 25 years. That supports the importance of research on mechanisms, but does not imply that this project will produce a biomarker or treatment. WHO fact sheet

Funding, Application, and Living Cost

The current award page states:

• Award: MRC FGx-DLA, four years; primary advertised project is full time.
• Stipend: £21,805 per year for 2026/27, updated annually.
• Tuition: The Exeter award page lists the UK tuition-fee level. The current FGx-DLA programme page says international students at Exeter do not need to supplement UKRI funding for the international-fee difference. Confirm that project 6025’s written offer follows this rule and check its year-specific fee schedule and any other charges.
• Research support: up to £5,000 per year for training and research support; this is not an additional living stipend.
• Application deadline: the current award page says 5 January 2027 for the Autumn 2027 competition. The project notice supplied for this research says 8 December 2026, with no cutoff time. Treat 8 December as the working deadline unless Exeter confirms in writing that the earlier date has been replaced.
• Eligibility: minimum 2:1 honours degree or international equivalent in a relevant field; typical English requirement IELTS 7.0 overall with no component below 6.5, or equivalent.
• Materials: online application, transcript(s), CV up to two pages, two references and FGx-DLA applicant questionnaire. One application per person can list up to three project preferences. Missing documents may prevent shortlisting; references must be arranged and submitted on the stated schedule. Exeter award page, FGx-DLA programme page

UKRI guidance describes provider-level options for the international-fee difference. The current FGx-DLA programme page gives the Exeter-specific rule: international students at Exeter do not have to supplement UKRI funding for that difference. As project 6025 is at Exeter, this resolves the programme-level top-up question, but the written offer should confirm the rule and state the applicable fee rates and any other charges. The number of international places is not stated. This tuition rule does not establish coverage of visa, travel, relocation, bench or other personal costs. UKRI training grant guidance, FGx-DLA international fee guidance

Exeter estimates basic living costs at £1,300–£2,000 per month, based on local spending in April 2026. The 2026/27 stipend equates to about £1,817 per month. That is within the published range, but the upper estimate annualizes to £24,000, about £2,195 more than the stipend before travel, visa, initial setup or other personal costs. Postgraduate accommodation examples range from roughly £124.74 per week for a standard self-catered room to £257.04 per week for a postgraduate studio; availability, bills and contract lengths vary. Recalculate against an actual housing option and personal travel/visa budget. Exeter budgeting guide, Exeter 2026/27 room finder, UKRI stipend-rate guidance

Applicant Fit and Preparation

Official requirements: a relevant 2:1 honours degree or equivalent. The DLA lists genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions, bioinformatics, computer science and statistics. The typical English requirement is IELTS 7.0 overall, minimum 6.5 in each component, or equivalent, with evidence by the applicable deadline. The project’s own PDF does not list mandatory previous ONT, wet-lab or programming experience.

Useful evidence to prepare: a research project showing experimental design or quantitative reasoning; examples of controls, quality checks, reproducible analysis or handling ambiguous results; and a clear interest in connecting molecular methods to human PD data. R/Python, statistics, multi-omics, mtDNA genetics, molecular biology and long-read sequencing are relevant preparation areas, but should be presented as useful fit evidence rather than formal project prerequisites. Candidates with mainly computational or mainly laboratory experience should explain how they would build competence in the other area. The work will involve interpretation under uncertainty: signal thresholds, sample heterogeneity, confounding and the difference between association and causal evidence. Exeter award page, project specification, Kouhsar profile

Research and Career Outlook

The UK life-sciences assessment projects 66,000 additional jobs in priority occupations between 2025 and 2035 in its central scenario, compared with 18,400 in an alternative scenario. It highlights digital, numeracy, scientific and regulatory skills. These projections are broad sector-level estimates, vary by scenario and cannot predict the outcome for an individual PhD graduate. Skills England life-sciences assessment

A historical HESA analysis of 2018/19 doctoral graduates found that 37% of biological-sciences PhD graduates were in higher-education research, and 89% of higher-education research roles were fixed term. This is not a current forecast, but it is a useful reminder that an academic research route often begins with temporary posts. Skills in ONT assay development, quality control, statistical genomics and multi-omics may also transfer to biotech, diagnostics and data-intensive life-sciences roles; the PhD itself does not guarantee any of these outcomes. Vitae doctoral graduate outcomes report

Next Actions and Questions to Verify

Before Applying

• Ask Professor Katie Lunnon and Exeter admissions whether the project-specific 8 December deadline still applies, the precise time zone/cutoff, and how it relates to the 5 January award deadline.
• Confirm that project 6025’s offer follows the current FGx-DLA no-top-up rule for international students at Exeter, ask for the year-specific fee schedule and other charges, and check whether international places are limited.
• Confirm the September 2027 start date, PGR registration route, campus/lab location and all documents that must arrive by the earlier date.
• Submit the online application and questionnaire early enough to resolve missing transcripts, certified translations, English evidence and references.

At Interview

• What is the cohort size, brain-region breakdown, sample quality/quantity, clinical metadata and status of ethics/data-access approvals?
• Which ONT chemistry, basecaller and modification-calling tools are planned? How will known 5mC, 5hmC and 6mA standards, negative controls and thresholds be chosen?
• What counts as a reproducible signal, and what are scientifically valid outcomes if a mark is absent, very low or inconsistent with earlier assays?
• Which existing bulk, single-nucleus, small-RNA, nuclear methylation and genetic datasets are available to the student, and what computational support/compute allocation is in place?
• Who is the primary day-to-day supervisor, how often will the team meet, and what training is planned for lab work and analysis?

Before Accepting an Offer

• Obtain written confirmation of stipend by year, the FGx-DLA no-top-up rule and applicable tuition rates, any other charges, research-support budget terms and project sequencing/consumable costs.
• Confirm project start date, registration institution, supervision structure and data-access timetable.
• Clarify how sample access and ethics governance are secured, and whether future mitochondrial epigenome editing is outside the funded doctoral scope.

Evidence and Sources

Project, award and programme

• Official Exeter project specification
• Exeter MRC FGx-DLA award page
• MRC Functional Genomics DLA programme

School, department and supervisors

• Exeter Clinical and Biomedical Sciences research themes
• Exeter rankings
• Exeter REF 2021 results
• Exeter Biological Sciences research degrees
• Professor Katie Lunnon profile
• Dr Morteza Kouhsar profile
• MRC Cambridge Chinnery Group
• Exeter Oxford Nanopore DNA sample guidance

Scientific publications and disease context

• Devall et al. (2022), human-brain mtDNA methylation
• Bicci et al. (2021), ONT and CpG methylation
• Stoccoro et al. (2021), PD blood D-loop methylation
• Smith et al. (2023), ONT profiling abstract
• Harvey et al. (2026), Lewy-body methylation meta-analysis
• Abu Manneh et al. (2026), early-onset PD mtDNA marks
• Choza et al. (2025), 5mC/5hmC in PD human brain
• Beglarian et al. (2025), PD cerebellum mtDNA copy number
• Wang et al. (2024), blood mtDNA copy number and cell composition
• WHO Parkinson disease fact sheet

Funding, costs and career context

• FGx-DLA international fee guidance
• UKRI international fee guidance
• UKRI 2026/27 stipend-rate table
• Exeter student budgeting guide
• Exeter postgraduate accommodation finder
• Skills England life-sciences skills assessment
• Vitae doctoral graduate outcomes report